SCHEMBL517072

SCHEMBL517072

CC(C)N(C)C(=O)C1CCC(NS(=O)(=O)c2ccc(N)c(N)c2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.46
LMNA P02545 4/20 0.43
PARG Q86W56 1/20 0.42
KMT2A Q03164 3/20 0.42
TDP1 Q9NUW8 1/20 0.42
KDM4E B2RXH2 2/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
CACNA1B Q00975 1/20 0.40
APBA1 Q02410 1/20 0.40
PIK3CD O00329 2/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CB P42338 1/20 0.40
PIK3CG P48736 1/20 0.40
PIK3R2 O00459 1/20 0.40
PIK3R1 P27986 1/20 0.40
PIK3R3 Q92569 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
GAA P10253 1/20 0.40
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL517073 1.00 ALDH1A1 (0.46) ALDH1A1LMNAPARGKMT2ATDP1
SCHEMBL516836 0.81 ALDH1A1 (0.46) ALDH1A1LMNAPARGKMT2ATDP1
SCHEMBL516837 0.81 ALDH1A1 (0.46) ALDH1A1LMNAPARGKMT2ATDP1
SCHEMBL517185 0.77 POLB (0.54) ALDH1A1PARGKMT2ASMN1; SMN2TP53
SCHEMBL517186 0.77 POLB (0.54) ALDH1A1PARGKMT2ASMN1; SMN2TP53
SCHEMBL517233 0.76 CNR1 (0.46) ALDH1A1LMNAKMT2ATDP1SMN1; SMN2
SCHEMBL517232 0.76 CNR1 (0.46) ALDH1A1LMNAKMT2ATDP1SMN1; SMN2
SCHEMBL12970920 0.73 ALDH1A1 (0.67) ALDH1A1LMNAPARGKMT2ATDP1
SCHEMBL12970919 0.73 ALDH1A1 (0.67) ALDH1A1LMNAPARGKMT2ATDP1
SCHEMBL516905 0.72 IDH2 (0.45) ALDH1A1PARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9789118-B2 Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof NOVARTIS AG (CH) 2017-10-17 US disclosed
US-20140171363-A1 BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2014-06-19 US disclosed
US-8697739-B2 Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof NOVARTIS AG (CH) 2014-04-15 US disclosed
US-20120028969-A1 BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140171363-A1 BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF ACACA, ACACB, COASY ALDH1A1 215/4885LMNA 2697/4885PARG 3356/4885
US-20120028969-A1 BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF ACACA, ACACB, COASY ALDH1A1 215/4885LMNA 2697/4885PARG 3356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.